At Carlat we dig deeper: Last fall it was the possibility of suicidality with antidepressants when we see the real data; this winter, it was the lack of clinical relevance of CYP enzyme testing when we use medications carefully; and this spring, beneath the apparent weight of thousands of studies that turn out to be flawed, we found an absence of a definable effect size for the massive $17 billion applied behavioral analysis industry.

In this first issue of 2021, we dig deeper into current and chronic areas of clinical complexity. Genetic testing can find identifiable disorders, offering relief to families searching for answers and perhaps guiding future treatment. Despite the hype, though, pharmacogenetics has limitations; we need to know what it can and...

As we head back into our homes in the midst of bungled reopenings and anguished protests, we at CCPR are striving to more consciously address social determinants and inequities. In this long-planned issue on culture, we talk about approaches to understanding cultural diversity in our everyday practice, the risks and...

What do you do when your teen patient declines an offer of medication yet the parents insist on it? How about if the teen is coming to you for medication and the parents are opposed to the idea?